Check out The cardiotoxicity of antimalarials
WHO Evidence Review Group Meeting, 13–14 October 2016
Varembé Conference Centre, Geneva, Switzerland
(Apart from halofantrine, the oral antimalarial drugs, particularly chloroquine and
piperaquine, have been used extensively with very few reports of cardiotoxicity.) page 11.
(There were no reports of serious adverse events of sudden death, TdP/QT interval prolongation
or cardiac arrhythmias within 14 days of follow-up after antimalarial therapy.) page 24
Now pay attention to this last part. (Despite hundreds of millions of doses administered in the treatment of malaria, there have been
no reports of sudden unexplained death associated with quinine, chloroquine or amodiaquine,
although each drug causes QT/QTc interval prolongation. Unfortunately, there are relatively few
prospective studies of the electrocardiographic effects of these drugs.
Intravenous chloroquine, quinine and quinidine may cause lethal hypotension if administered too
rapidly. Large doses (>3.5mg base/kg) of intramuscular or subcutaneous chloroquine may also
cause hypotension.) page 36